Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

More than 1 in 3 parents reported that their child has dealt with dental problems linked to a lack of routine oral hygiene, such as brushing teeth twice daily, a new poll shows.

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

In his new action movie ‘Flight Risk’, Mark Wahlberg plays a villain – and you can tell because his character is balding. It’s the latest in a long line of films that uses an absence of hair as a visual cue for evil,